AbbVie Says Latest FDA Approval Expands Botox Use Beyond Face
Express News | Abbvie Inc - Phase III Studies Show Significant Improvement With Botox Cosmetic
Express News | Botox® Cosmetic (Onabotulinumtoxina) Receives FDA Approval for Moderate to Severe Vertical Bands Connecting the Jaw and Neck (Platysma Bands)
BOTOX Cosmetic (OnabotulinumtoxinA) Receives FDA Approval for Moderate to Severe Vertical Bands Connecting the Jaw and Neck (Platysma Bands)
AbbVie (ABBV): Growth Driven by Skyrizi, Rinvoq, and Strategic Acquisitions
FDA Approves AbbVie's VYALEV as First 24-Hour Levodopa Infusion for Advanced Parkinson's
AbbVie Price Target Raised to $195.00/Share From $185.00 by B of A Securities
Analysts Revise AbbVie Stock Price Target Ahead of Earnings
BofA Securities Initiates AbbVie(ABBV.US) With Hold Rating
Analysts Offer Insights on Healthcare Companies: Merit Medical Systems (MMSI), AbbVie (ABBV) and Elevance Health (ELV)
REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting
AbbVie (ABBV) Falls More Steeply Than Broader Market: What Investors Need to Know
Bernstein: First time covering eli lilly and co, gilead sciences and amgen, all with an "outperform large cap" rating.
Bernstein initiates coverage on eli lilly and co, gilead sciences, and amgen with an "outperform" rating. Bernstein stated that the bullish ratings on gilead and amgen are based on optimistic expectations for revenue growth from key assets from now until 2030, including gilead's HIV PreEP treatment lenacapavir, amgen's weight loss drug MariTide, and rare disease investment portfolio. As for eli lilly and co, Bernstein stated that the rating "depends on how it uses the cash generated from weight loss drugs", eli lilly and co is ready to leverage a diversified investment portfolio and drive growth through weight loss drugs. In addition, Bern
Market Analysis: AbbVie And Competitors In Biotechnology Industry
AbbVie Is Maintained at Outperform by BMO Capital
BMO Capital Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $220
AbbVie Is Doing 'Very Well' But Jim Cramer's Favorite? Abbott Laboratories
AbbVie Wins FDA Nod for Infusion Treatment for Advanced Parkinson's Disease
AbbVie Wins FDA Nod for Advanced Parkinson's Therapy
U.S. FDA Approves VYALEV For Adults Living With Advanced Parkinson's Disease